Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
Under Trump, Future Of Harm Reduction Policies To Curb Drug Overdoses Is Unclear
U.S. needs to pursue evidence-based interventions for substance use disorders. It’s unclear to what degree the Trump ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
'This is about fentanyl': Tariffs are crucial to combating 'drug war,' Trump and Cabinet officials say
Trump administration says tariffs on Mexico, Canada and China critical to preventing fentanyl and other drugs from pouring ...
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...
Trump's administration aims for 'greater transparency' in drug price negotiations
The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...
WMBD Peoria on MSN1h
New type of non-opioid pain medication approved by FDA
( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...
What is Non-Opioid Pain Medication? Journavx Approved by FDA
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.